Characterization of triple or penta-refractory senior patients with relapsed/refractory myeloma exposed to elranatamab: A real-world experience. Grant

Characterization of triple or penta-refractory senior patients with relapsed/refractory myeloma exposed to elranatamab: A real-world experience. .

date/time interval

  • April 1, 2025 - June 30, 2026

awarded by

subcontracted through

administered by

sponsor award ID

  • Agreement 06/16/2026

local award ID

  • AWD000000018491

contributor